Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2020-07-22 Regulatory Filings
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT : premières décisions concernant la nouvelle orientation stratégique
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces key strategic decisions, including the closure of a Phase 3 clinical trial (RESOLVE-IT) and the prioritization of other programs (PBC development and NIS4TM technology). It provides financial and operational updates but is not a comprehensive annual report (10-K), a detailed interim report (IR), or a formal regulatory filing like a DEF 14A or a DVA. Since it is an official announcement detailing business updates, strategic shifts, and clinical trial outcomes, it most closely aligns with an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS) if it doesn't fit elsewhere. However, given the nature of the announcement—a major strategic pivot and clinical trial update released outside of a standard quarterly earnings cycle (dated July 22, 2020, referencing a May 11, 2020, publication)—it functions as a significant, immediate corporate disclosure. In the context of the provided definitions, it is a high-impact announcement that doesn't fit the specific financial report types (10-K, IR, AR, ER). It is a general corporate announcement, making 'RNS' (Regulatory Filings / General regulatory announcements) the most appropriate fallback, although 'ER' (Earnings Release) is sometimes used broadly for major operational updates. Given the focus on strategic direction and clinical trial termination rather than just financial results highlights, RNS is safer, but since it contains significant operational news, I will check if it fits better elsewhere. It is not a presentation (IP), a management discussion (MDA), or a proxy statement (PSI). It is a press release announcing major corporate news. In many databases, such non-standard, material news releases default to a general filing category. I will classify it as RNS as the best fit for a material, non-standard announcement.
2020-07-22 French
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Capital/Financing Update Classification · 99% confidence The document is titled "GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial" and explicitly states it is reporting data as of "June 30, 2020," covering the "first half of 2020." This structure—a report detailing financial/contractual activity over a specific interim period (six months)—strongly indicates an Interim/Quarterly Report (IR). Although the content is specifically about a liquidity contract, the format and period covered align best with the comprehensive reporting expected in an IR, rather than a brief Earnings Release (ER) or a general Regulatory Filing (RNS). The document length (17,046 chars) is substantial, ruling out the 'Report Publication Announcement' (RPA) based on the 'MENU VS MEAL' rule, as this appears to be the report content itself.
2020-07-10 English
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
Regulatory Filings Classification · 99% confidence The document is titled "GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial" (GENFIT: Semi-annual statement of the liquidity contract entered into with Crédit Industriel et Commercial). It reports on the status of a liquidity contract as of June 30, 2020, detailing the number of shares and cash held, and the volume of shares traded (purchases and sales) during the first semester (H1) of 2020. This type of periodic report concerning financial arrangements, specifically liquidity management, is not explicitly covered by the main financial report codes (10-K, IR) or standard corporate actions (DIV, SHA). It is a specific financial disclosure related to market operations. Since it is a periodic report detailing financial activity over a defined period (H1 2020), it aligns most closely with the comprehensive nature of an Interim/Quarterly Report (IR), although it focuses narrowly on the liquidity contract. However, given the specific nature of reporting on a liquidity contract balance, it is a specialized financial disclosure. If we consider the options, it is a periodic financial update. It is not an Earnings Release (ER) as it doesn't contain P&L/Balance Sheet highlights, nor is it a standard Interim Report (IR) which usually covers full operational results. It is a report on a specific financial arrangement. Since there is no specific code for 'Liquidity Contract Report', and it is a detailed report covering a half-year period, it is best classified as an Interim Report (IR) as it covers a period shorter than a year, or potentially as a Regulatory Filing (RNS) if it's considered a miscellaneous mandatory disclosure. Given the detailed financial figures provided for the period, classifying it as an Interim Report (IR) is the most appropriate fit among the provided options for a comprehensive period-based financial document, even if narrowly focused. If it were just an announcement *about* this report, RPA would apply, but the text contains the full data tables. I will classify it as IR based on the semi-annual reporting period and detailed financial data.
2020-07-10 French
GENFIT: Enhances Board of Directors with Two Strategic Appointments
Board/Management Information Classification · 99% confidence The document is explicitly titled 'PRESS RELEASE' and announces the appointment of two new members to the company's Board of Directors following the annual Shareholders Meeting. This content directly relates to changes in the company's governing body, which aligns perfectly with the definition for Board/Management Information (MANG). It is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (PSI).
2020-07-07 English
GENFIT : Résultats de l’assemblée générale ordinaire du 30 juin 2020
AGM Information Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its main subject is announcing the "Résultats de l'assemblée générale ordinaire du 30 juin 2020" (Results of the ordinary general meeting of June 30, 2020). It details that all resolutions were adopted and provides a link where the detailed voting results can be found. This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Although it is a press release, the core information is the voting outcome, making DVA the most specific classification over a general RPA or RNS.
2020-06-30 French
GENFIT: June 30, 2020 Annual Shareholders Meeting results
AGM Information Classification · 98% confidence The document is explicitly titled "GENFIT: June 30, 2020 Annual Shareholders Meeting results" and details that "All of the resolutions were adopted by a large majority of the votes cast" during the Ordinary Shareholders' Meeting. This content directly relates to the official results of a shareholder vote at a general meeting. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA). Although it mentions the Annual Shareholders Meeting (AGM), the focus is on the *results* of the vote, not the presentation materials (AGM-R) or the proxy solicitation (DEF 14A/PSI).
2020-06-30 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.